The investigational device has the potential to transform a half-century-old standard of care.

The randomized, multi-center study, LIGHTSITE III, enrolled the last patient at the Byers Eye Institute at Stanford University in Palo Alto, CA with Principal Investigator, Diana Do, M.D. 

JAMA network study.

Horst Sievert, MD, Director of the CardioVascular Center in Frankfurt, Germany, and Tamaz Shaburishvili, MD, Head of the Cardiovascular Clinic at Tbilisi Heart and Vascular Clinic in Tbilisi, Georgia, shared preliminary results of the clinical trial as part of a CSI Focus D-HF webinar presented last week.

Turkish Journal of Medical Sciences Key study findings show 20% faster procedure time for simulation training, 30% less cartilage damage during simulation training, VR Simulators as effective as “gold standard” cadavers for training arthroscopic procedures.

The objective of the study is to collect ‘real-world’ safety, efficacy, health economics, and patient-reported quality-of-life data in over 700 patients with PAD treated with SELUTION SLR.